Compare Alcon AG (ALC) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs H2O America — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while H2O America trades at $61.46 (market cap $2.58B). The key difference: Alcon AG is far larger — about 12.7× H2O America's market cap, and H2O America pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| ALC | HTO | |
|---|---|---|
Market Cap | $32.69B | $2.58B |
Sector | Health | Technology |
52-Week High | $92.22 | $62.42 |
52-Week Low | $62.02 | $44.44 |
Enterprise Value | $36.28B | $4.31B |
Dividend Yield | 0.54% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
HTO trades at $61.21, down 1.94% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $61.33. The company reported Q1 2026 EPS of $0.50, beating expectations, and maintains strong fundamentals with a 12.87% net income margin. Recent news highlights executive appointments and institutional investments, reinforcing positive sentiment.
The stock presents a balanced opportunity with steady earnings growth and a reliable dividend, but faces risks from high RSI levels indicating overbought conditions and substantial capital expenditures. Analyst consensus is strongly bullish with 80% buy ratings, though investors should monitor execution of growth initiatives and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
